Transcriptomic Features Associated With Kinase Inhibitor Sensitivity in KMT2A-Rearranged AML.
Certain genetic patterns in aggressive blood cancer correlate with sensitivity to kinase inhibitors, helping narrow treatment options in the laboratory.
This retrospective transcriptomic drug-sensitivity analysis examined Transcriptomic Features Associated With Kinase Inhibitor Sensitivity in KMT2A-Rearranged AML. A KMT2A -r-like transcriptomic state is associated with candidate kinase inhibitor sensitivity patterns in primary AML datasets and appears linked to, but not fully explained by, FLT3 -related biology.
What the study was
- Study design
- Retrospective transcriptomic drug-sensitivity analysis
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Cancer genomics & proteomics
Why it surfaced
Abstract-backed retrospective transcriptomic drug-sensitivity analysis relevant to Hematologic malignancies (AML, MDS, CLL, MPN, lymphoma); scored conservatively because full text was not assessed.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.